Open AccessHigh-Intensity Focused Ultrasound Enhanced Anti-Tumor Activities of Paclitaxel in Breast Cancer in vitro and in vivo
Author(s) -
Sha Chen,
Hao Bian,
Jingyu Duan
Publication year - 2022
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
ISSN - 1179-1322
DOI - 10.2147/cmar.s349409
Subject(s) - paclitaxel , in vivo , breast cancer , high intensity focused ultrasound , apoptosis , medicine , viability assay , cancer research , annexin , cancer , chemistry , pharmacology , biology , ultrasound , biochemistry , microbiology and biotechnology , radiology
Paclitaxel (PTX) is an important oncologic chemotherapeutic agent against breast cancer, but breast cancer patients develop significant resistance to PTX during chemotherapy. Alterations in tubulin and associated proteins have been implicated in resistance to PTX. High-intensity focused ultrasound (HIFU) induces deep tumor penetration of anti-tumor agents in solid tumors.